



PRESS RELEASE

ASLAN PHARMACEUTICALS ANNOUNCES POSTER PRESENTATION AT ESMO ASIA CONGRESS 2017

Singapore, 8 November 2017 – ASLAN Pharmaceuticals (ASLAN; 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it will be presenting data from its phase 2 trial of *varlitinib* in metastatic HER2-positive breast cancer patients at the ESMO Asia Congress 2017. The congress will take place from 17-19 November at Suntec Singapore Convention & Exhibition Centre in Singapore.

Varlitinib is a reversible potent small molecule inhibitor of the HER-family of receptor tyrosine kinases (RTKs).

Details of the abstract are as follows:

Title: Multicenter Phase 2 trial of *varlitinib* versus *lapatinib* in combination with capecitabine in patients with HER2+ metastatic breast cancer (MBC) who failed prior trastuzumab therapy.

Abstract Number: 987

A full-text version of the abstract has been made available online at
<https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/presentation/list?r=pt~23>

Ends

Media contact

Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333
E-mail: media@aslanpharma.com

Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: ASLAN@spurwingcomms.com

About *varlitinib* (ASLAN001)

Varlitinib (ASLAN001) is a potent, reversible, small molecule inhibitor of EGFR, HER2, HER3 and HER4. In a large variety of cancers, the overexpression and/or constitutive activation of EGFR and HER2 are often observed and frequently correlate with poor clinical prognosis. Therefore, by inhibiting the activation of the HER receptors via *varlitinib*, effects such as shrinkage of the tumour and longer survival can be expected. *Varlitinib* is currently being studied in biliary tract, breast and gastric cancers. *Varlitinib* has been granted orphan drug status in the USA for cholangiocarcinoma and gastric cancer and was awarded orphan drug status for the treatment of advanced biliary tract cancer after first line systemic therapy by the Korean MFDS.



About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (6497.TT) is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia. The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and colorectal cancer, with the lead programme in pivotal studies. ASLAN's partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL.

www.aslanpharma.com